ASTERIAS BIOTHERAPEUTICS, INC. AST Cash Flow

Asterias biotherapeutics, inc. (AST)

CashFlow / Quarterly

Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
-4,454	-6,982	-2,312	-6,548	-6,809	-8,728	-6,287	-9,345	-10,648	-5,159	-10,337	-4,905	-3,508	-3,617	-2,973	-3,326	-1,682	-2,802	-2,286	-17,565	-2,665	-1,334	-815	-758
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
248	252	261	-	285	276	279	-	304	303	302	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,459	0	0	0	0
Depreciation and amortization expense
-	-	-	-	-	-	-	-	-	-	-	168	132	132	132	121	140	138	130	125	58	25	10	0
Stock-based compensation
719	751	590	1,549	907	991	997	1,149	1,171	869	1,608	1,507	616	809	693	414	395	746	258	262	418	19	2	0
Amortization of intangible assets
671	671	672	672	671	671	672	672	671	671	672	671	672	671	672	2,677	703	683	725	725	0	0	0	0
Amortization of prepaid rent
-	-	-	-	-	-	-	-	-	-	-	22	21	21	21	22	21	20	21	-	-	-	-	0
Gain on sale of equipment, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	2	0	0	0
Deferred income tax benefit
-	-	-	-	-	-	-	-70	-902	-451	-902	-2,866	-1,561	-1,241	-1,584	-2,201	-2,313	-1,512	-1,349	-3,281	0	0	0	0
Common stock issued for services in lieu of cash
167	170	306	293	296	288	274	278	0	319	325	486	0	0	0	-	-	-	-	-	-	-	-	-
Gain from change in fair value of warrant liability
169	366	1,519	2,504	506	-56	2,954	-740	-3,996	1,628	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Distribution of Asterias warrants to shareholders other than BioTime, Inc.
-	-	0	-	-	-	-2,042	0	-2,160	0	-3,125	0	0	0	0	-	-	-	-	-	-	-	-	-
Gain from change in fair value of marketable equity securities
830	-1,695	1,435	-	-118	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Grant receivable
-	-	-	-	-	-	-	-	-	-	-	0	0	0	-118	118	0	0	0	-	-	-	-	0
Prepaid expenses and other current assets
100	-371	-69	0	634	-391	-256	-68	383	448	124	225	224	138	93	170	69	-127	70	202	10	-20	230	2
Other assets
-306	205	-136	-251	-590	-2	-3	-2	-3	-2	-3	-3	98	0	0	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	436	389	-1,434	938	289	-336	-331	354	301	132	-232	-80	213	144	209	0	0
Accounts payable, accrued expenses and other current liabilities
190	445	-708	-	431	-647	-554	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
-	-	-	-	-	-	-	1,238	-666	1,116	175	-156	490	-45	295	154	-134	58	120	-138	206	19	8	0
Deferred rent
-	5	4	-	-	16	13	14	25	25	23	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-58	-	0	0	0	-	-	-	-	0
Lease liability
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-
Deferred grant income
-	-	0	-	-	-	-1,894	793	-1,857	979	-243	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant income
-	-	-	-	-	-	-	-	-	-	-	-	-8	403	1,474	-	0	0	0	-	-	-	-	-
Amount due to BioTime
-	-	-	-	-	-	-	-9	307	-843	303	-	-	-	-	-	-	-	-	-	-	-	-	-
Amount due to parent, BioTime, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	248	-	-5,027	2,286	1,082	-728	2,874	1,677	1,078	761
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-4,132	-	-3,647	-4,033	-701	-1,823	-7,834	-485	-1,448	-	-	-	-	0
Net cash used in operating activities
-2,908	-3,193	-3,936	-5,785	-4,524	-6,975	-7,153	-	-	-	-	-	-	-	-	-	-	-	-	-	1,025	638	54	-
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment
0	0	0	53	158	65	14	251	144	436	63	119	35	143	16	-85	2	101	96	-353	1,027	573	0	0
Proceeds from the sale of marketable equity securities
257	998	1,483	-	281	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of security deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	7	300	0	0	0	54	0
Reimbursement of security deposit
-	-	0	-	-	-	25	-	-1	0	32	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on construction in progress
-	-	-	-	-	-	-	-	-	-	6	449	1,312	2,222	296	219	0	0	0	-	-	-	-	-
Proceeds from sale of equipment and furniture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	27	0	0	0
Net cash provided by investing activities
257	998	1,483	678	123	-90	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-999	-573	-54	-
CASH FLOWS FROM FINANCING ACTIVITIES:
Financing costs for sale of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	0	598	0	-	-	-	-	-	-	-	-	-
Reimbursement of security deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Net cash provided by/(used in) investing activities
-	-	-	-	-	-	-	-	-	-	-37	-	-1,348	-2,365	-312	-134	-2	12,552	-396	-	-	-	-	0
Proceeds from sale of common stock under at-the-market transactions
0	1,167	0	-1	1,307	1,025	5,671	5,820	1,972	6	171	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing costs for at-the-market sales
0	36	0	0	40	42	156	254	68	0	6	-	-	-	425	-	-	-	-	-	-	-	-	-
Proceeds from sale of common shares
-	-	-	-	-	-	-	-	-	-	-	-	0	8,286	0	-	0	468	0	0	0	0	0	0
Proceeds from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	0	0	6,200	5,500	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
0	0	0	-5	3	18	2	93	0	1,926	7	6	0	23	0	-	-	-	-	-	-	-	-	0
Repayment of lease liability and capital lease obligation
-	138	134	-	-	120	116	112	311	-96	100	1	0	0	0	-	-	-	-	-	-	-	-	-
Shares retired to pay for employees' taxes
0	0	160	0	0	0	0	34	32	17	85	98	0	0	0	-	-	-	-	-	-	-	-	-
Reimbursement from landlord on construction in progress
-	-	-	-	-	-	-	0	0	0	567	1,225	2,004	277	283	0	0	0	0	-	-	-	-	-
Payment to Geron in connection with acquisition of assets on October 1, 2013
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	228	0	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	554	-	2,004	14,613	5,358	8	0	468	0	-	-	-	-	0
Net cash provided by financing activities
-142	993	-294	9,753	1,146	881	5,401	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
NET DECREASE IN CASH AND CASH EQUIVALENTS
-	-	-2,747	-	-	-	-1,741	1,874	-3,543	13,901	-3,615	-1,462	-2,991	8,215	4,345	-1,949	-7,836	12,535	-1,845	2,079	26	65	0	0
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid during the period
112	117	122	-	0	135	139	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fully vested common stock and restricted stock units issued in payment for accrued employee bonuses
0	0	951	-	0	0	720	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of equipment and furniture, contributed by BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	459	0	0	0	0
Construction in progress in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Landlord receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Lease liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Available-for-sale BioTime securities contributed by BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34,985	0	0	0	0
Cancellation of indebtedness to BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,000	0	0	0	0
Transaction costs paid by BioTime, on behalf of the Company
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Intangible assets acquired from Geron
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29,017	0	0	0	0
Adjustment to deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Investment in affiliates, contributed by BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	416	0	0	0	0
Common stock and common stock warrants issued to BioTime and Geron in connection with acquisition and transfer of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74,098	0	0	0	0
Common stock issued upon investment by BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	50
Reduction of subscriptions receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-50	0	0	0	0
Common stock issued in exchange for non-cash consideration in connection with investment by officer
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1